Developer docs
API playgroundTry for free, no card

Search company profiles

Da Volterra

Full company profile

uuid000hmu9

Namestring
Da Volterra
Websiteurl
davolterra.com
Company typeenum
Private
Founded yearint
2000
Descriptiontext

Da Volterra is a clinical-stage biopharmaceutical company headquartered in Paris, France, founded in 2000. According to the firm's own positioning, the company innovates for better health and care for people worldwide, consistent with the stated mission and product strategy of European clinical-stage biopharma developers.

The company is structured around developing pharmaceutical products intended for broad patient and healthcare-system impact, though the input data does not specify a therapeutic area, lead asset, mechanism of action, modality, or pipeline stage. No platform architecture, technology stack, proprietary features, patents, or scientific publications are documented in the input; consequently, the specific scientific basis of Da Volterra's pipeline cannot be characterized from the supplied evidence.

Organizationally, Da Volterra is a private, for-profit entity led by CEO Florence Séjourné, with co-founder Antoine Andremont retained in a Scientific Advisor capacity. The input provides no information on headcount, funding history, partnerships, clinical milestones, customer relationships (not applicable pre-commercial), pricing, or revenue model. As a clinical-stage biopharma, the implied business model is one of equity-based funding of clinical development, with future commercialization via direct launch, partnership, or out-licensing — but none of these revenue mechanics are documented in the input data.

Short descriptiontext

Da Volterra is a private, clinical-stage biopharmaceutical company founded in 2000 and headquartered in Paris, France, developing pharmaceutical innovations intended to improve health and care for people worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
clinical-stage biopharmaceutical, antimicrobial resistance drugs, microbiome preservation therapeutics, antibiotic protection medicines, infectious disease treatments
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Scientific Research and Development Services5417
Product category
Clinical-stage biopharmaceutical drug development
Social media profiles2 records
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Da Volterra is a clinical-stage biopharmaceutical company that develops therapeutic products aimed at addressing antimicrobial resistance and preserving the gut microbiome during antibiotic treatments. The company focuses on innovative drug development to improve health outcomes for patients worldwide through microbiome-protective pharmaceutical solutions.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

The source data pertains to SPOTBET, an online gambling platform. No Da Volterra product information is present in the source data.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

French clinical-stage biopharmaceutical company developing microbiome-based therapeutics for oncology and gut-related diseases. It is the closest geographic and therapeutic-area peer to Da Volterra, both targeting the gut microbiome with regulated drug products.

TypeDirect peer
Description

US-listed clinical-stage company developing microbiome therapeutics, including an approved C. difficile infection therapy. Directly comparable to Da Volterra on indication (CDI), mechanism (microbiome restoration), and clinical-stage business model.

TypeDirect peer
Description

Clinical-stage company developing defined bacterial consortia for recurrent C. difficile infection and other microbiome-mediated diseases. Overlaps with Da Volterra on CDI indication and microbiome-drug regulatory pathway.

TypeDirect peer
Description

Pioneer of live biotherapeutic products for recurrent C. difficile infection, now part of Ferring. Directly comparable to Da Volterra on therapeutic area, modality (microbiome therapeutics), and indication overlap.

TypeDirect peer
Description

Clinical-stage developer of microbiome-based therapeutics including programs targeting C. difficile infection and inflammatory bowel disease. Comparable to Da Volterra on microbiome-modality and clinical-stage profile.

TypeEmerging player
Description

Paris-based biotech developing microbiome-targeted engineered phage therapies. Comparable to Da Volterra through its Paris location, microbiome focus, and clinical-stage drug development approach, though targeting a narrower precision-microbiome niche.

TypeBroad incumbent
Description

Clinical-stage biopharmaceutical company developing novel antibiotics for C. difficile infection and other serious infectious diseases. Comparable to Da Volterra on anti-infective therapeutic focus and clinical-stage model.

TypeDirect peer
Description

Clinical-stage company developing antibiotics against resistant pathogens, including oral and IV candidates targeting complicated urinary tract infections. Comparable to Da Volterra on anti-infective clinical development.

9Nabriva Therapeutics
TypeDirect peer
Description

Clinical-stage biopharma developing antibiotics for community-acquired pneumonia and other serious infections. Comparable on therapeutic area, clinical-stage model, and anti-infective commercial focus.

TypeBroad incumbent
Description

Established global biopharmaceutical company with a leading microbiome franchise (Rebiotix). Comparable to Da Volterra through its CDI-treating microbiome assets and as a likely strategic acquirer of microbiome-stage companies.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Da Volterra

Clinical-stage biopharmaceutical drug developmentdavolterra.com

Da Volterra is a private, clinical-stage biopharmaceutical company founded in 2000 and headquartered in Paris, France, developing pharmaceutical innovations intended to improve health and care for people worldwide.

What Da Volterra does

Da Volterra is a clinical-stage biopharmaceutical company headquartered in Paris, France, founded in 2000. According to the firm's own positioning, the company innovates for better health and care for people worldwide, consistent with the stated mission and product strategy of European clinical-stage biopharma developers.

The company is structured around developing pharmaceutical products intended for broad patient and healthcare-system impact, though the input data does not specify a therapeutic area, lead asset, mechanism of action, modality, or pipeline stage. No platform architecture, technology stack, proprietary features, patents, or scientific publications are documented in the input; consequently, the specific scientific basis of Da Volterra's pipeline cannot be characterized from the supplied evidence.

Organizationally, Da Volterra is a private, for-profit entity led by CEO Florence Séjourné, with co-founder Antoine Andremont retained in a Scientific Advisor capacity. The input provides no information on headcount, funding history, partnerships, clinical milestones, customer relationships (not applicable pre-commercial), pricing, or revenue model. As a clinical-stage biopharma, the implied business model is one of equity-based funding of clinical development, with future commercialization via direct launch, partnership, or out-licensing — but none of these revenue mechanics are documented in the input data.

Da Volterra firmographics

Firmographics
Name
Da Volterra
Website
https://davolterra.com
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
1–10 employees
Short description
Da Volterra is a private, clinical-stage biopharmaceutical company founded in 2000 and headquartered in Paris, France, developing pharmaceutical innovations intended to improve health and care for people worldwide.
Ownership category
akta.pro rank

Where Da Volterra is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Markets served

Da Volterra business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Da Volterra product offering

Product offering

Core offering

Da Volterra is a clinical-stage biopharmaceutical company that develops therapeutic products aimed at addressing antimicrobial resistance and preserving the gut microbiome during antibiotic treatments. The company focuses on innovative drug development to improve health outcomes for patients worldwide through microbiome-protective pharmaceutical solutions.

Product overview

The source data pertains to SPOTBET, an online gambling platform. No Da Volterra product information is present in the source data.

Differentiator

Problem solved

Functional benefit

Companies that use Da Volterra

Customer profile

Ideal customer profiles2 records

Da Volterra technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Da Volterra partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights1 record

Da Volterra competitors and assessment

Company assessment

Direct peers

  • MaaT Pharma: French clinical-stage biopharmaceutical company developing microbiome-based therapeutics for oncology and gut-related diseases. It is the closest geographic and therapeutic-area peer to Da Volterra, both targeting the gut microbiome with regulated drug products.
  • Seres Therapeutics: US-listed clinical-stage company developing microbiome therapeutics, including an approved C. difficile infection therapy. Directly comparable to Da Volterra on indication (CDI), mechanism (microbiome restoration), and clinical-stage business model.
  • Vedanta Biosciences: Clinical-stage company developing defined bacterial consortia for recurrent C. difficile infection and other microbiome-mediated diseases. Overlaps with Da Volterra on CDI indication and microbiome-drug regulatory pathway.
  • Rebiotix (Ferring Pharmaceuticals): Pioneer of live biotherapeutic products for recurrent C. difficile infection, now part of Ferring. Directly comparable to Da Volterra on therapeutic area, modality (microbiome therapeutics), and indication overlap.
  • Finch Therapeutics: Clinical-stage developer of microbiome-based therapeutics including programs targeting C. difficile infection and inflammatory bowel disease. Comparable to Da Volterra on microbiome-modality and clinical-stage profile.
  • Iterum Therapeutics: Clinical-stage company developing antibiotics against resistant pathogens, including oral and IV candidates targeting complicated urinary tract infections. Comparable to Da Volterra on anti-infective clinical development.
  • Nabriva Therapeutics: Clinical-stage biopharma developing antibiotics for community-acquired pneumonia and other serious infections. Comparable on therapeutic area, clinical-stage model, and anti-infective commercial focus.

Emerging players

  • Eligo Bioscience: Paris-based biotech developing microbiome-targeted engineered phage therapies. Comparable to Da Volterra through its Paris location, microbiome focus, and clinical-stage drug development approach, though targeting a narrower precision-microbiome niche.

Broad incumbents

  • Summit Therapeutics: Clinical-stage biopharmaceutical company developing novel antibiotics for C. difficile infection and other serious infectious diseases. Comparable to Da Volterra on anti-infective therapeutic focus and clinical-stage model.
  • Ferring Pharmaceuticals: Established global biopharmaceutical company with a leading microbiome franchise (Rebiotix). Comparable to Da Volterra through its CDI-treating microbiome assets and as a likely strategic acquirer of microbiome-stage companies.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Da Volterra social profiles

Digital presence

Da Volterra financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Da Volterra leadership team

Management profile

Number of profiles

Profiles2 records

Da Volterra funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Da Volterra M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Da Volterra

What does Da Volterra do?

Da Volterra is a clinical-stage biopharmaceutical company that develops therapeutic products aimed at addressing antimicrobial resistance and preserving the gut microbiome during antibiotic treatments. The company focuses on innovative drug development to improve health outcomes for patients worldwide through microbiome-protective pharmaceutical solutions.

When was Da Volterra founded?

Da Volterra was founded in 2000. It employs 1 to 10 people.

Where is Da Volterra based?

Da Volterra is headquartered in Paris, France, in the Europe region.

Who are Da Volterra's main competitors?

Direct peers on record are MaaT Pharma, Seres Therapeutics, Vedanta Biosciences, Rebiotix (Ferring Pharmaceuticals), Finch Therapeutics, Iterum Therapeutics and Nabriva Therapeutics. Eligo Bioscience is listed as an emerging player. Broad incumbents are Summit Therapeutics and Ferring Pharmaceuticals.

Does Da Volterra have an API?

No public API is recorded for Da Volterra.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales